Original Contribution |
From the Division of Cardiovascular Research (T.M., Z.L., K.W.), St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass; the Department of Medicine, Division of Cardiology (S.L.M.), and the Department of Developmental and Molecular Biology (S.L.M., T.E.), Albert Einstein College of Medicine, Bronx, NY.
Correspondence to Kenneth Walsh, PhD, Division of Cardiovascular Research, St. Elizabeth's Medical Center, Tufts University School of Medicine, 736 Cambridge St, Boston, MA 02135. E-mail kwalsh{at}opal.tufts.edu
| Abstract |
|---|
|
|
|---|
ZF). Adenovirus-mediated
GATA-6 gene transfer to the vessel wall after balloon
injury partially restored the levels of GATA-6 protein and DNA-binding
activity to before injury levels. The local delivery of Ad-GATA6 but
not Ad-GATA6
ZF inhibited lesion formation by 46% relative to saline
control and 50% relative to a control adenovirus that expressed
lacZ. Local delivery of Ad-GATA6 also reversed changes
in the expression patterns of smooth muscle myosin heavy chain, smooth
muscle
-actin, calponin, vinculin, metavinculin, and proliferating
cell nuclear antigen that are associated with injury-induced VSMC
phenotypic modulation. These data indicate that the injury-induced
downregulation of GATA-6 is an essential feature of VSMC phenotypic
modulation that contributes to vessel lesion formation.
Key Words: gene expression adenovirus restenosis muscle, smooth genes
| Introduction |
|---|
|
|
|---|
The GATA family of transcriptional regulatory proteins includes 6 vertebrate genes, which each contain a highly conserved zinc-finger DNA-binding domain that interacts with DNA regulatory elements that contain a consensus A/T GATA A/G (WGATAR) or related sequence. The vertebrate GATA factors are categorized into 2 subfamilies. Each of the GATA-1/2/3 genes is essential for a distinct function in hematopoietic cell development,5 whereas the GATA-4/5/6 genes are each expressed in cells of the cardiovascular system and endoderm-derived tissues, including the gut.5 GATA-4 can affect cardiogenesis in vitro,6 7 and it can regulate cardiac musclespecific gene expression by transactivating promoters that contain the GATA consensus binding site.8 9 10 In vivo, GATA-4/5/6 can activate muscle-specific genes,11 although its primary functions are more firmly established in the regulation of embryonic morphogenesis in mouse12 13 and chick.14 Additional data from the frog system also suggest that GATA-6 can play a role in regulating cell proliferation during cardiogenesis.11 Although the expression patterns for the GATA-4/5/6 genes largely overlap during early embryogenesis, GATA-6 transcript levels are particularly high in the developing cardiac outflow tract.12 13 Expression patterns for GATA-4 and GATA-6 diverge with the onset of vasculogenesis; only GATA-6 is expressed in the medial smooth muscle cells of the vasculature.15 Although its function in smooth muscle is undefined, GATA-6 appears to be the major GATA factor expressed in cultured VSMCs.15 16 By analogy to related family members, GATA-6 is likely to regulate the differentiation state of VSMCs in vivo.
Previously, we reported on GATA-6, the primary structure of the human protein, localized the chromosomal location to 18q11.118q11.2 and described the tissue-restricted transcription pattern in human tissues.16 We also demonstrated that GATA-6 is expressed in quiescent rat and human VSMCs in culture and that mitogen activation of these cultures led to a rapid and transient downregulation of expression with kinetics similar to that exhibited by gas and gadd genes.17 18 These data suggested that GATA-6 might function to coordinate the expression of VSMC-contractile genes with genes required for cell-cycle progression. Recently, we also demonstrated that plasmid-mediated overexpression of GATA-6 inhibits mitogen-induced cell cycle activity in VSMCs and fibroblasts in vitro.19 Therefore, GATA-6 is an excellent candidate for a lineage-restricted regulatory protein that can regulate VSMC phenotype in proliferative lesions of the vessel wall.
In this study, we examined the regulation and function of GATA-6 during the proliferative response of VSMCs to acute injury. Balloon injury of adult rat carotid arteries results in rapid VSMC loss due to apoptotic cell death20 followed by the temporally and spatially coordinated initiation of the cell cycle in the remaining VSMCs.21 VSMCs that proliferate then migrate to the lumen and form a neointimal lesion by 2 weeks.22 In this study, we show that GATA-6 is downregulated during the peak of proliferative activity after balloon injury. To determine the functional significance of this downregulation, adenovirus-mediated GATA-6 gene transfer to balloon-injured rat carotid arteries was performed, which resulted in restoration of GATA-6 expression. Although before injury levels were not achieved, vessels transduced with the GATA-6encoding adenovirus displayed a higher degree of VSMC differentiation and a reduced level of intimal hyperplasia. These data suggest that GATA-6 controls VSMC phenotype in vivo and that suppression of this factor may contribute to the pathogenesis of VSMC-derived lesions.
| Materials and Methods |
|---|
|
|
|---|
Adenoviral Vector Construction
A cDNA encoding the full-length human GATA-6 protein was
isolated from pCDNA-GATA-6wt19 and inserted into the
KpnI-XbaI sites of pACCMV.pLpA, which contains a
CMV promoter/enhancer, SV40 polyA tract, and the Ad5 adenoviral
sequences required for homologous recombination to generate the
plasmid pACCMV.pLpA-GATA-6wt. A cDNA that contained a deletion in the
zinc-finger region, which results in expression of a protein that
lacks codons 244 to 306, was subcloned similarly into pACCMV.pLpA to
generate pACCMV.pLpA-GATA-6-
ZF. Each plasmid and pJM17 was
cotransfected into 293 cells, which allowed for homologous
recombination.24 The E1-/E3-deleted adenovirus constructs
that contained GATA-6wt (Ad-GATA6) or GATA-6-
ZF (Ad-GATA6-
ZF)
were purified from isolated plaques, identified by polymerase chain
reaction (PCR) and immunoblotting analysis, and
amplified in 293 cells. The viral preparations used for both in vitro
and in vivo studies were purified by CsCl gradient
ultracentrifugation and dialyzed against buffer, which
contained 10 mmol/L Tris-HCl and 10% glycerol. The titer of
recombinant adenoviruses was determined by plaque assay on 293 cells as
described previously25 and expressed as plaque-forming
units (PFU)/mL. The replication-defective adenoviral construct
Ad-ßgal expresses ß-galactosidase from the CMV promoter.
Rat Model of Balloon Injury and Adenoviral Infection
The rat carotid artery balloon-injury model was based on a
model described by Clowes et al.22 Adult male
Sprague-Dawley rats that weighed 400 to 600 g were subjected to a
distending, deendothelializing injury with an inflated
2F Fogarty embolectomy catheter inserted through the external carotid
artery. The injured segment of artery was then incubated in the absence
or presence of adenovirus (1.0x109 PFU) in a
total volume of 100 µL saline for 20 minutes. Rats were killed at 1,
3, or 14 days after injury with an intraperitoneal
injection of pentobarbitol (100 mg/kg). The balloon-injured segment of
the artery from the proximal edge of the omohyoid muscle to the carotid
bifurcation was perfused with saline and dissected. The tissue was then
fixed with 100% methanol and embedded in paraffin.
Histological images of 4 µmol/L cross sections
from the center of the injured segment were hematoxylin-eosin or
elastic-trichrome stained and used to determine the intimal, medial,
and luminal areas by quantitative morphometric analysis with a
computerized sketching program (MACMEASURE version 1.9). Three sections
from each artery were evaluated by an investigator who was blinded to
the identities of the treatment groups. Experimental protocol was
approved by the Institutional Animal Care and Use Committee of
St. Elizabeth's Medical Center and complied with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals.
Cell-Cycle Analysis
Primary cultures of rat VSMCs were infected at a MOI of 300 PFU
per cell with Ad-ßGAL, Ad-GATA6
ZF, or Ad-GATA6 for 12 hours, after
which the virus was removed and cultures were incubated in
low-mitogen media for an additional 12 hours. Growth media was then
added for 24 hours, and cells were harvested by trypsinization, fixed,
and stained with propidium iodide.26 Quiescent cells were
harvested after 72 hours in low-mitogen media without infection. DNA
content was analyzed by flow cytometry, and the cell-cycle
profile was determined with a Beckton Dickinson Vantage flow cytometer
and Lysis II cell cycle analysis software.
Immunoblot Analysis
Cells were infected with the indicated adenovirus at an MOI of
100 (NIH3T3 and 10.1 cells) or 300 (rat VSMCs) as described above.
Whole cell extracts from rat carotid arteries and cultured cells were
prepared in ice-cold lysis buffer (1% NP-40, 9.1 mmol/L dibasic
sodium phosphate, 1.7 mmol/L monobasic sodium phosphate, 150
mmol/L NaCl, 1 mmol/L DTT, 0.5 mmol/L PMSF, 2 µg/mL
aprotinin, 2 µg/mL leupeptin, 1 mmol/L sodium orthovanadate) and
then centrifuged. Arterial extracts were prepared
from a pool of 4 or 5 arteries with a homogenizer
(Tissumizer Mark II; Tekmar Co). Immunoblot
analyses used rabbit polyclonal antibody against human GATA-6
protein, as described previously,19 mouse monoclonal
antiproliferating cell nuclear antigen (PCNA; Signet Laboratories,
Dedham, Mass), rabbit polyclonal anti-Cdk4 (C22, Santa Cruz, Calif),
mouse monoclonal antismooth muscle myosin (hSM-V), mouse monoclonal
anticalponin (hCP), mouse monoclonal antivinculin (hVIN-1; Sigma) and
mouse monoclonal anti
-tubulin (Calbiochem). Arterial
segments were harvested at 24 hours, 72 hours, 7 days, and 14 days
after balloon injury and treatment, and contralateral carotid arteries
were taken as uninjured control arteries. Western
immunoblot analyses were preformed on 10 to 75 µg
of carotid artery extract protein, which depended on signal intensity
as described previously.19 All immunoblot
experiments were performed on at least 3 separate occasions.
Electrophoretic Mobility Shift Assays
Whole-cell lysates were prepared from rat carotid arteries,
NIH3T3 cells, or 10.1 fibroblasts that were uninfected or infected with
the indicated adenoviral construct in ice-cold lysis buffer (50
mmol/L Hepes, pH 7.8; 420 mmol/L KCl; 0.1 mmol/L EDTA, pH
8.0; 5 mmol/L MgCl2; 20% glycerol; 1
mmol/L DTT; 0.5 mmol/L PMSF; 2 µg/mL aprotinin; 2 µg/mL
leupeptin; and 1 mmol/L sodium orthovanadate) by subjecting tissue
or cells to 3 cycles of freezing and thawing followed by
centrifugation. Double-stranded
oligonucleotide probes and competitor DNAs were
synthesized to correspond to the extensively characterized GATA
consensus site in the
-globin promoter.15 The coding
strand sequence for each probe was
GATA 5'-GATCTCCGGCAACTGATAAGGATTCCCTG-3'
GATA mt 5'-GATCTCCGGCAACTAGCTAGGATTCCCTG-3'
The consensus and mutated GATA-binding sites are underlined. Electrophoretic mobility shift assays (EMSAs) were performed as described previously.19 Supershift assays were performed with rabbit polyclonal antiGATA-6 antibody or preimmune serum.19 All EMSA experiments were performed on at least 3 separate occasions.
RNA Isolation and Reverse TranscriptionPCR Analysis on
Balloon-Injured Rat Carotid Arteries
Individual arteries were isolated from each rat and immediately
frozen in liquid nitrogen. For each sample, the tissue was transferred
to a 50-mL polypropylene tube that contained 2 mL of TRI reagent (MRC)
and homogenized with a hand-held tissue-tearer
(Biospec Products). RNA was isolated after extraction by
isopropanol precipitation. After the nucleic acids were washed in 70%
ethanol, they were resuspended and the DNA was removed by digestion
with 1 U of RQ1 RNAse-free DNAse (Promega Corp) for 10 minutes at
37°C. RNA was purified by phenol-chloroform extraction, precipitated
by ethanol, and resuspended in H2O. RNA
concentration was determined by optical density and then diluted to 0.1
mg/mL.
Each RNA sample was reverse-transcribed at 37°C for 1 hour in a
20-µL reaction that contained 100 pmol/L random hexamer pdN6
(Pharmacia) and 40 U murine leukemia virus reverse transcriptase
(Gibco/BRL). Under standard conditions, each sample contained 0.5 µg
of RNA. In some control experiments, 0.25 µg of RNA was used to
ensure that the signal generated by PCR quantitatively reflected the
RNA added. For PCR, 2 µL of each reverse transcription (RT) reaction
was used in a 20-µL reaction, which contained 1.5 mmol/L
MgCl2, 1.0 mmol/L concentration of each
primer, 200 µmol/L dNTPs, and 0.1 µL of
32P-dCTP as a
tracer for qualifying the products. Primer sequences were
GATA-6, forward: 5'-CCC AGC GCA GAC CTG TTG GAG GAC C
GATA-6, reverse: 5'-TGT GAC AGT TGG CAC AGG ACA G
GAPDH, forward: 5'-GAT GGT GAA GGT CGG TGT CAA
GAPDH, reverse: 5'-CAC CAC CTT CTT GAT GTC ATC
Cycling parameters for each primer pair were analyzed independently in preliminary experiments. Products were shown to accumulate linearly in accordance with cycle number and were directly dependent on the amount of RNA added to in the RT reaction. Each PCR was initiated with a 2-minute denaturing incubation at 95°C and ended with a 10-minute extension at 72°C. The cycle parameters were 30 seconds at 95°C, 45 seconds at 58°C, and 45 seconds at 72°C. The number of cycles used for GATA-6 and GAPDH was 26 and 24, respectively. Products were separated by electrophoresis in 5% polyacrylamide nondenaturing gels. Phosphorimage analysis was performed with a Molecular Dynamics Storm 860 phosphorimaging system to quantify the relative levels of GATA-6 and GAPDH PCR product.
Statistical Analysis
Results were expressed as the mean±SEM. In the
fluorescence-activated cell sorter (FACS)
analyses, statistical significance was evaluated by ANOVA
followed by Scheffé's procedure. In the RT-PCR analysis,
statistical significance was analyzed at the 3-day time point,
the nadir of GATA-6 downregulation, with a paired Student
t test. Statistical significance was assumed when the
probability of a null hypothesis was <0.05.
| Results |
|---|
|
|
|---|
-tubulin
levels were detected in these extracts, which indicated equal protein
loading.
|
EMSAs were performed to examine GATA-6 DNA-binding activity in whole
cell extracts prepared from injured and noninjured rat carotid
arteries. With the use of extracts prepared from an uninjured artery, a
diffuse nucleoprotein complex was detected with a radiolabeled duplex
oligonucleotide probe that corresponded to the GATA
site derived from a mouse
-globin promoter (Figure 2A
). This nucleoprotein complex was not
detected when the DNA-binding mixture contained a 100-fold molar excess
of unlabeled consensus oligonucleotide probe, whereas
in a parallel reaction, a 100-fold molar excess of probe that contained
a mutation in the GATA consensus sequence was unable to compete for
complex formation. The presence of GATA-6 protein in the nucleoprotein
complex was demonstrated by the ability to supershift complex with
antiGATA-6 antibodies raised to regions of the GATA-6 protein that
were not homologous to the other GATA proteins (Figure 2B
).
Inclusion of preimmune serum did not alter the nucleoprotein complex.
Collectively, these data demonstrate that GATA-6 DNA-binding activity
can be detected in extracts prepared from rat carotid arteries.
|
GATA-6 DNA-binding activity was decreased in extract prepared from
arteries at 1 or 3 days after injury compared with uninjured vessels,
but DNA-binding activity recovered to preinjury levels at 7 and 14 days
after injury (Figure 2C
). The changes in GATA-6 DNA-binding
activity parallel closely the changes in GATA-6 protein levels (Figure 1
). The same EMSA results were obtained with GATA consensus DNA
sequences from the mouse
globin promoter (Figure 2
), the
GATA/CEF-1 binding site from the murine cardiac troponin C gene that
binds GATA-6,15 or the GATA consensus binding site from
the human T-cell receptor
gene27 (data not shown).
Previous work in cultured VSMCs indicated that steady-state
GATA-6 transcript levels decreased after
mitogen-activated cell proliferation.16 To
investigate this regulation in vivo, transcript levels of
GATA-6 and GAPDH (as a control) were measured in
balloon-injured and uninjured rat carotid arteries by a
semiquantitative RT-PCR assay under conditions that ensured a linear
accumulation of signal with respect to input RNA and cycle number. An
advantage of this RT-PCR approach is that RNA from individual arteries
could be analyzed, which allowed a statistical
analysis. The results confirmed the Western blotting
experiments, which showed that GATA-6 transcript levels
(relative to the control GAPDH mRNA) decreased significantly
3 days after balloon injury (Figure 3A
).
At day 3, transcript levels decreased nearly 3-fold (0.37±0.12
relative to 1.0 for uninjured arteries; Figure 3B
). These
results are consistent with a primary effect on the
GATA-6 gene at the mRNA level after vessel injury in
vivo.
|
Construction and Characterization of Replication-Defective
Adenoviral Vectors Expressing GATA-6 cDNAs
Because the GATA-6 gene is regulated at the transcript level after
stimulation of VSMC proliferation, it was reasonable to consider
whether forced transcription to restore levels might inhibit intimal
hyperplasia in the rat model of balloon injury. For this purpose,
replication-defective adenoviral vectors were constructed to express
GATA-6 (Ad-GATA6) or a mutant nonDNA-binding GATA-6 (Ad-GATA6
ZF)
that lacks a large portion of the zinc-finger DNA-binding domain
(Figure 4A
). In preliminary cell culture
experiments, Western immunoblot analysis of NIH3T3
cells revealed prominent immunoreactive bands that migrate with an
apparent molecular weight of 52 kDa in the Ad-GATA6infected cells and
46 kDa in the Ad-GATA6
ZFinfected cells, which is
consistent with the predicted molecular weight of the wild-type
and mutant GATA-6 proteins (Figure 4B
).
|
To confirm the expected activity of the wild-type and mutant
proteins, whole-cell lysates from NIH3T3 cells infected with Ad-GATA6
were used in gel mobility shift experiments, which showed a significant
increase in the predominant nucleoprotein complex (Figure 4C
, arrowhead) relative to lysates from uninfected cells (the NIH3T3
lysates contain low levels of an endogenous GATA-binding
activity). This complex was competed specifically with excess
unlabeled target site probe but not by the mutant probe (Figure 4C
). The inclusion of specific antiGATA-6 antibodies gave a
supershifted complex, whereas preimmune sera had no effect. No increase
in specific binding activity was detected in lysates of NIH3T3 cells
infected with Ad-GATA6
ZF or the control virus that expresses
ß-galactosidase, Ad-ßgal. Therefore, with respect to DNA-binding
activity, these data show that Ad-GATA6 expresses functional GATA-6
protein, whereas Ad-GATA6
ZF does not.
Previously, we reported that plasmid-encoded GATA-6 inhibits cell
growth.19 Thus, FACS analysis was performed to
test whether the GATA-6expressing adenoviral vectors also inhibit
cell cycle activity (Table
). Quiescent
VSMCs were transduced with adenoviral constructs and stimulated with
high-mitogen media. Ad-GATA6 transduced cells were arrested in G0/G1
phases of the cell cycle, comparable to uninfected quiescent cells. In
contrast, FACS analyses revealed that mitogen-stimulated cells
transduced with Ad-GATA6
ZF or Ad-ßgal were comparable to
mock-infected, mitogen-stimulated cells. Infection with Ad-GATA6 also
led to a corresponding decrease in the proportion of cells in S phase
compared with Ad-GATA6
ZF, Ad-ßGal, or mock-infected cells. These
data demonstrate that adenovirus-mediated overexpression of GATA-6
inhibits cell growth in vitro but the GATA-6 mutant lacking the
zinc-finger domain does not.
|
Ad-GATA6 Inhibits Neointima Formation in
Balloon-Injured Carotid Arteries
To test the activity of GATA-6 in vivo, the adenoviral constructs
were used to deliver wild-type and mutant GATA-6 locally to
balloon-injured rat carotid arteries. Immediately after denudation with
a balloon catheter, the vessel wall was exposed to adenoviral solution
(1.0x109 PFU) for 20 minutes. Arteries were
harvested 1 or 3 days afterward to examine protein expression by
immunoblot analysis or EMSA or at 2 weeks to assess
intimal hyperplasia. Immunoblot analysis revealed
that local delivery of Ad-GATA6 partially restores GATA-6 protein
levels at the 3-day postinjury time point (Figure 5A
). Similar results were also observed
with extracts prepared from vessels at 1 day after injury (not shown).
Gel mobility shift experiments revealed that the injury-induced
decrease in GATA-6 DNA-binding activity levels was partially reversed
when assessed at day 3 (Figure 5B
) or day 1 (not shown)
postinjury. Therefore, adenovirus-mediated GATA-6 gene transfer results
in restoration of GATA-6 expression, although at lower levels relative
to uninjured vessels.
|
Immunoblot analysis revealed that expression of
PCNA, a marker of VSMC proliferation, was suppressed in extracts
prepared from Ad-GATA6infected vessels, relative to saline injected
controls (Figure 5A
). Analyses of PCNA staining of
histological sections at 3 days after injury revealed
that the expression of PCNA-positive cells in Ad-GATA6treated vessels
was reduced by a factor of 3.2 relative to the saline control
(P<0.01), whereas the Ad-ßgal and
Ad-GATA6
ZFtreated vessels displayed 14% more (not statistically
significant) or 9% fewer (not statistically significant) PCNA-positive
cells, respectively, than the saline control (data not shown).
Therefore, similar to its antiproliferative function in vitro, forced
expression of GATA-6 appears to inhibit cell growth in the vessel
wall.
Western immunoblot analyses were performed on
injured vessels to examine the effects of constitutive GATA-6
expression on markers of smooth muscle cell differentiation. Smooth
muscle myosin heavy chain (SM MHC), smooth muscle
-actin (SM
-actin), and calponin expression and the ratio of metavinculin to
vinculin expression are indicative of smooth muscle cell
differentiation in developing vessels and vascular
disease.28 As expected, vascular injury downregulated the
expression of SM MHC, SM
-actin, and calponin, whereas the
expression of the cyclin-dependent kinase cdk4 did not change (Figure 6
). Injury also increased the ratio of
vinculin to metavinculin expression, which is consistent with
reports that this ratio is indicative of VSMC differentiation in adult
human tissues.29 30 Infection of vessels with Ad-GATA6 at
the time of injury attenuated the downregulation of SM MHC, SM
-actin, and calponin. In contrast, vinculin was reduced to near
preinjury levels by the partial restoration of GATA-6 expression. These
data suggest that GATA-6 regulates the differentiated phenotype
of VSMCs under conditions that induce intimal lesions.
|
Finally, restoration of GATA-6 expression had a significant effect on
lesion formation at 2 weeks after injury. Saline-treated arteries and
Ad-ßGalinfected arteries had neointima/media (I/M) area
ratios of 1.4±0.14 and 1.3±0.13, respectively. In contrast, arteries
infected with Ad-GATA6 had an I/M ratio of 0.70±0.13
(P<0.01), which represented a 46% to 50%
reduction relative to saline and Ad-ßGalinfected arteries (Figure 7
). Local delivery of Ad-GATA6
ZF did
not significantly inhibit neointima formation (I/M ratio of
1.2±0.13). Collectively, these data indicate that relatively low
levels of GATA-6 expression in the vessel wall can inhibit
injury-induced stenosis in the rat carotid model.
|
| Discussion |
|---|
|
|
|---|
In this study, we examined the role of GATA-6 in the genesis of a proliferative lesion in the blood vessel wall. GATA-6 regulation and function was examined in balloon-injured rat carotid arteries, a well-characterized model that induces robust VSMC proliferation and produces a lesion that partially occludes the lumen of the vessel. Downregulation of the GATA-6 protein was noted at 1 and 3 days after injury, which corresponds to a peak of proliferative activity in medial VSMCs.21 22 Levels of GATA-6 protein returned to normal after 7 days, and this level of expression was maintained at 14 days after injury. At these later time points, medial smooth muscle cell proliferation has ceased, whereas smooth muscle cells at the luminal edge of the lesion continue to proliferate.21 The time course of GATA-6 depletion and recovery was closely paralleled by changes in GATA-6 DNA-binding activity. Furthermore, GATA-6 mRNA levels also decreased and then recovered after balloon injury, which is consistent with the notion that the gene is regulated at the transcriptional level in balloon-injured vessels. This aspect is important because translational controls might preclude restoration of GATA-6 levels by gene transfer techniques. The time course of GATA-6 downregulation and recovery in injured carotid arteries was similar to that of Gax, another mitogen-regulated transcription factor in VSMCs that can inhibit cell growth.26 37
To determine the functional significance of GATA-6 downregulation in vivo, replication-defective adenoviral constructs that expressed functional or nonfunctional GATA-6 cDNAs were constructed and used to deliver these transgenes locally to the sites of vascular injury. Adenovirus-mediated delivery of the wild-type GATA-6 gene inhibited intimal hyperplasia by 50%, relative to a control adenovirus that expressed lacZ, whereas adenovirus-mediated delivery of a mutated GATA-6 cDNA did not inhibit lesion formation. Note that although adenovirus-mediated GATA-6 gene transfer resulted in elevation of GATA-6 protein and DNA-binding activity at 1 and 3 days after injury, preinjury levels were not achieved. Therefore, physiological levels of GATA-6 appear to be critical to determining the size of the injury-induced lesion. In contrast, the efficacy of other gene products for inhibition of vascular lesion progression appears to require extensive overexpression.38 39
GATA-6mediated inhibition of intimal lesion formation probably results from the ability of this factor to promote VSMC differentiation and inhibit mitogen-activated cell-cycle activity. It has been shown previously that plasmid-mediated overexpression of GATA-6 can inhibit the proliferation of VSMCs and fibroblasts.19 In this study, we show that PCNA expression, a marker of VSMC proliferation, was reduced in the GATA-6-transduced vessels, which suggests that GATA-6 has antiproliferative properties in vivo. The importance of cell-cycle activity during intimal hyperplasia is underscored by the observation that injury-induced lesion formation is inhibited by molecules that can interfere with cell-cycle progression. For example, intimal hyperplasia is inhibited by antisense cdk2 oligonucleotides40 and by overexpression of both the wild-type and mutant forms of the retinoblastoma protein39 41 or the cdk inhibitor p21.38
During VSMC phenotypic modulation, proliferation is accompanied by a
reversion of VSMCs to a less differentiated, fibroblast-like state.
Thus, it has been suggested that the same subset of transcription
factors that regulate cell division might also be important in
controlling the expression of tissue-specific genes associated with the
differentiated state.35 36 In this study, we have shown
that restoration of GATA-6 expression in balloon-denuded arteries
attenuates the changes in SM MHC, SM
-actin, calponin, vinculin, and
metavinculin expression that occur with injury-induced VSMC phenotypic
modulation. Although direct transcriptional links between GATA-6 and
these genes have not been demonstrated to date, many contain consensus
WGATAR sequences (GATA-6 binding sites) in their promoters. Of note,
vinculin and metavinculin are alternative splice products of a
single gene,28 which suggests that GATA-6 can control
numerous regulatory processes within VSMCs, including
posttranscriptional mechanisms. Surprisingly, the GATA-6-induced VSMC
differentiation was not observed when cultured rat or human VSMCs
were infected with the Ad-GATA6 construct (T.M., K.W., unpublished
observations, 1998). These data suggest that extracellular
components present within the intact vessel wall are essential for
GATA-6induced expression of differentiation-specific genes.
Many diseases of the vessel wall are associated with the dedifferentiation and excessive proliferation of VSMCs. In this study, we demonstrated that the levels of GATA-6 transcript, protein, and DNA-binding activities are decreased in the vessel wall after acute injury and that lesion formation is inhibited by the partial restoration of GATA-6 expression. These data indicate that GATA-6 downregulation after injury is an essential feature of the proliferative response to vessel wall injury. Identification of GATA-6 as an endogenous regulator of pathological VSMC proliferation may provide insights about the molecular mechanisms that contribute to vascular lesions and may have implications for the development of new therapies to treat these diseases.
| Acknowledgments |
|---|
Received August 20, 1998; accepted January 13, 1999.
| References |
|---|
|
|
|---|
2. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Salter LF, Popma JJ, Wong SC, Leon MB. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol. 1995;26:720724.[Abstract]
3.
Dilley RJ, McGeachie JK, Prendergast FJ. A review of
the histologic changes in vein-to-artery grafts, with particular
reference to intimal hyperplasia. Arch Surg. 1988;123:691696.
4.
Braun-Dullaeus R, Mann M, Dzau V. Cell cycle
progression: new therapeutic target for vascular proliferative disease.
Circulation. 1998;98:8289.
5. Simon MC. Gotta have GATA. Nat Genet. 1995;11:911.[Medline] [Order article via Infotrieve]
6. Grépin C, Nemer G, Nemer M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development. 1997;124:23872395.[Abstract]
7. Grépin C, Robitaille L, Antakly T, Nemer M. Inhibition of transcription factor GATA-4 expression blocks in vitro cardiac muscle differentiation. Mol Cell Biol. 1995;15:40954102.[Abstract]
8. Durocher D, Charron F, Warren R, Schwartz R, Nemer M. The cardiac transcription factors Nkx2.5 and GATA-4 are mutual cofactors. EMBO J. 1997;16:56875696.[Medline] [Order article via Infotrieve]
9. Durocher D, Nemer M. Combinatorial interactions regulating cardiac transcription. Dev Genet. 1998;22:250262.[Medline] [Order article via Infotrieve]
10. McGrew M, Bogdanova N, Hasegawa K, Hughes S, Kitsis R, Rosenthal N. Distinct gene expression patterns in skeletal and cardiac muscle are dependent on common regulatory sequences in the MLC1/3 Locus. Mol Cell Biol. 1996;16:45244534.[Abstract]
11. Jiang Y, Evans T. The Xenopus GATA-4/5/6 genes are associated with cardiac specification and can regulate cardiac-specific transcription during embryogenesis. Dev Biol. 1996;174:258270.[Medline] [Order article via Infotrieve]
12.
Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement
of the transcription factor GATA4 for heart tube formation and ventral
morphogenesis. Genes Dev. 1997;11:10611072.
13.
Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM,
Parmacek MS, Soudais C, Leiden JM. GATA4 transcription factor is
required for ventral morphogenesis and heart tube formation.
Genes Dev. 1997;11:10481060.
14. Jiang Y, Tarzami S, Burch JB, Evans T. Common role for each of the cGATA-4/5/6 genes in the regulation of cardiac morphogenesis. Dev Genet. 1998;22:263277.[Medline] [Order article via Infotrieve]
15. Morrisey EE, Ip HS, Parmacek MS. GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm. Dev Biol. 1996;177:309323.[Medline] [Order article via Infotrieve]
16. Suzuki E, Evans T, Lowry J, Truong L, Bell DW, Testa JR, Walsh K. The human GATA-6 gene: structure, chromosomal location and regulation of expression by tissue-specific and mitogen-responsive signals. Genomics. 1996;38:283290.[Medline] [Order article via Infotrieve]
17. Fornace AJ, Jackman J, Hollander MC, Hoffman-Liebermann B, Liebermann DA. Genotoxic-stress-response genes and growth arrest genes: gadd, MyD, and other genes induced by treatments eliciting growth arrest. Ann N Y Acad Sci. 1992;663:139153.[Medline] [Order article via Infotrieve]
18. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 1988;54:787793.[Medline] [Order article via Infotrieve]
19.
Perlman H, Suzuki E, Simonson M, Smith RC, Walsh K.
GATA-6 induces p21Cip1 expression and
G1 cell cycle arrest. J Biol
Chem. 1998;273:1371313718.
20.
Perlman H, Maillard L, Krasinski K, Walsh K. Evidence
for the rapid onset of apoptosis in medial smooth muscle cells
following balloon injury. Circulation. 1997;95:981987.
21. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andrés V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418426.
22. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327333.[Medline] [Order article via Infotrieve]
23. Mader SL. Influence of animal age on the ß-adrenergic system in cultured rat aortic and mesenteric artery smooth muscle cells J Gerontol. 1992;47:B32B36.[Abstract]
24. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology. 1992;20:363390.[Medline] [Order article via Infotrieve]
25. Graham FL, van der Eb AJ. A new technique for assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456467.[Medline] [Order article via Infotrieve]
26.
Smith RC, Branellec D, Gorski DH, Guo K, Perlman H,
Dedieu JF, Pastore C, Mahfoudi A, Denèfle P, Isner JM, Walsh K.
p21CIP1-mediated inhibition of cell proliferation
by overexpression of the gax homeodomain gene. Genes
Dev. 1997;11:16741689.
27.
Ko L, Yamamoto M, Leonard M, George K, Ting P, Engel J.
Murine and human T-lymphocyte GATA-3 factors mediate transcription
through a cis-regulatory element within the human T-cell
receptor delta gene enhancer. Mol Cell Biol. 1991;11:27782784.
28.
Owens GK. Regulation of differentiation of vascular
smooth muscle cells. Physiol Rev. 1995;75:487517.
29. Brinck U, Mirzaie M, Korabiowska M, Meyer T. Expression rate of vinculin isoforms in human aortocoronary saphenous vein grafts. Int J Cardiol. 1997;59:125132.[Medline] [Order article via Infotrieve]
30.
Glukhova M, Kabakov A, Frid M, Ornatsky O, Belkin A,
Mukhin D, Orekhov A, Koteliansky V, Smirnov V. Modulation of human
aorta smooth muscle cell phenotype: a study of muscle-specific
variants of vinculin, caldesmon, and actin expression. Proc Natl
Acad Sci U S A. 1988;85:95429546.
31.
Chamley-Campbell J, Campbell GR, Ross R. The smooth
muscle cell in culture. Physiol Rev. 1979;59:161.
32. Campbell GR, Campbell JH. Phenotypic modulation of smooth muscle cells in primary culture. In: Campbell JH, Campbell GR, eds. Vascular Smooth Muscle in Culture. Boca Raton, Fla: CRC Press Inc; 1987:I39I55.
33.
Aikawa M, Sivam PN, Kuro-o M, Kimura K, Nakahara K,
Takewaki S, Ueda M, Yamaguchi H, Yazaki Y, Periasamy M, Nagai R. Human
smooth muscle myosin heavy chain isoforms as molecular markers for
vascular development and atherosclerosis. Circ
Res. 1993;73:10001012.
34.
Chen YH, Chen YL, Lin SJ, Chou CY, Mar GY, Chang MS,
Wang SP. Electron microscopic studies of phenotypic modulation of
smooth muscle cells in coronary arteries of patients with
unstable angina pectoris and postangioplasty restenosis.
Circulation. 1997;95:11691175.
35. Walsh K, Perlman H. Molecular strategies to inhibit restenosis: modulation of the vascular myocyte phenotype. Semin Interv Cardiol. 1996;1:173179.[Medline] [Order article via Infotrieve]
36. Gorski DH, Walsh K. Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Cardiovasc Res. 1995;30:585592.[Medline] [Order article via Infotrieve]
37.
Weir L, Chen D, Pastore C, Isner JM, Walsh K.
Expression of GAX, a growth-arrest homeobox gene, is rapidly
down-regulated in the rat carotid artery during the proliferative
response to balloon injury. J Biol Chem. 1995;270:54575461.
38. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:22602268.
39.
Smith RC, Wills KN, Antelman D, Perlman H, Truong LN,
Krasinski K, Walsh K. Adenoviral constructs encoding
phosphorylation-competent full-length and truncated
forms of the human retinoblastoma protein inhibit myocyte proliferation
and neointima formation. Circulation. 1997;96:18991905.
40. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leynen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:14581464.
41.
Chang MW, Barr E, Seltzer J, Jiang Y, Nabel GJ, Nabel
EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular
proliferative disorders with a constitutively active form of the
retinoblastoma gene product. Science. 1995;267:518522.
This article has been cited by other articles:
![]() |
N. Y. Tan, J.-M. Li, R. Stocker, and L. M. Khachigian Angiotensin II-Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement Circ. Res., August 28, 2009; 105(5): 422 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Shirvani, L. Mookanamparambil, M. F. Ramoni, and M. T. Chin Transcription factor CHF1/Hey2 regulates the global transcriptional response to platelet-derived growth factor in vascular smooth muscle cells Physiol Genomics, June 19, 2007; 30(1): 61 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takeji, T. Moriyama, S. Oseto, N. Kawada, M. Hori, E. Imai, and T. Miwa Smooth Muscle {alpha}-Actin Deficiency in Myofibroblasts Leads to Enhanced Renal Tissue Fibrosis J. Biol. Chem., December 29, 2006; 281(52): 40193 - 40200. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Herring, O. El-Mounayri, P. J. Gallagher, F. Yin, and J. Zhou Regulation of myosin light chain kinase and telokin expression in smooth muscle tissues Am J Physiol Cell Physiol, November 1, 2006; 291(5): C817 - C827. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, G. Hu, and B. P. Herring Smooth Muscle-Specific Genes Are Differentially Sensitive to Inhibition by Elk-1 Mol. Cell. Biol., November 15, 2005; 25(22): 9874 - 9885. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Deaton, C. Su, T. G. Valencia, and S. R. Grant Transforming Growth Factor-{beta}1-induced Expression of Smooth Muscle Marker Genes Involves Activation of PKN and p38 MAPK J. Biol. Chem., September 2, 2005; 280(35): 31172 - 31181. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yin and B. P. Herring GATA-6 Can Act as a Positive or Negative Regulator of Smooth Muscle-specific Gene Expression J. Biol. Chem., February 11, 2005; 280(6): 4745 - 4752. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Lepore, T. P. Cappola, P. A. Mericko, E. E. Morrisey, and M. S. Parmacek GATA-6 Regulates Genes Promoting Synthetic Functions in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 309 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Mann, J. L. Ray, E. S. Moon, K. M. Sass, and M. R. Benson Calcineurin initiates smooth muscle differentiation in neural crest stem cells J. Cell Biol., May 24, 2004; 165(4): 483 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Liu, M. Ikegami, M. T. Stahlman, C. R. Dey, and J. A. Whitsett Inhibition of alveolarization and altered pulmonary mechanics in mice expressing GATA-6 Am J Physiol Lung Cell Mol Physiol, December 1, 2003; 285(6): L1246 - L1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Taylor and C. A. McNamara Regulation of Vascular Smooth Muscle Cell Growth: Targeting the Final Common Pathway Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1717 - 1720. [Full Text] [PDF] |
||||
![]() |
Y. J. Suzuki, R. M. Day, C. C. Tan, T. H. Sandven, Q. Liang, J. D. Molkentin, and B. L. Fanburg Activation of GATA-4 by Serotonin in Pulmonary Artery Smooth Muscle Cells J. Biol. Chem., May 2, 2003; 278(19): 17525 - 17531. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kumar and G. K. Owens Combinatorial Control of Smooth Muscle-Specific Gene Expression Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 737 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abe, K. Hasegawa, H. Wada, T. Morimoto, T. Yanazume, T. Kawamura, M. Hirai, Y. Furukawa, and T. Kita GATA-6 Is Involved in PPAR{gamma}-Mediated Activation of Differentiated Phenotype in Human Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 404 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Yaar, L. M. Cataldo, A. Tzatsos, C. E. Francis, Z. Zhao, and K. Ravid Regulation of the A3 Adenosine Receptor Gene in Vascular Smooth Muscle Cells: Role of a cAMP and GATA Element Mol. Pharmacol., November 1, 2002; 62(5): 1167 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V. Ennezat, S. L. Malendowicz, M. Testa, P. C. Colombo, A. Cohen-Solal, T. Evans, and T. H. LeJemtel Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes J. Am. Coll. Cardiol., July 1, 2001; 38(1): 194 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Ellis, Q. Chen, P. J. Barker, J. C. Metcalfe, and P. R. Kemp Nov Gene Encodes Adhesion Factor for Vascular Smooth Muscle Cells and Is Dynamically Regulated in Response to Vascular Injury Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1912 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Kibbe, T. R. Billiar, and E. Tzeng Gene Therapy for Restenosis Circ. Res., April 28, 2000; 86(8): 829 - 833. [Full Text] [PDF] |
||||
![]() |
J. M. Miano, M. J. Carlson, J. A. Spencer, and R. P. Misra Serum Response Factor-dependent Regulation of the Smooth Muscle Calponin Gene J. Biol. Chem., March 24, 2000; 275(13): 9814 - 9822. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Molkentin The Zinc Finger-containing Transcription Factors GATA-4, -5, and -6. UBIQUITOUSLY EXPRESSED REGULATORS OF TISSUE-SPECIFIC GENE EXPRESSION J. Biol. Chem., December 8, 2000; 275(50): 38949 - 38952. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |